Results 31 to 40 of about 51,509 (201)

Decrease in outpatient department visits and operative interventions due to bisphosphonates in children with osteogenesis imperfecta

Journal of Children's Orthopaedics, 2011
Introduction Bisphosphonates are currently the medical treatment most often used in children with osteogenesis imperfecta (OI). The purpose of this retrospective pre–post study was to evaluate the efficacy of treatment with bisphosphonates.
F. de Graaff, W. Verra, J. E. H. Pruijs, R. J. B. Sakkers   +3 more
doaj   +1 more source

Osteonecrose da mandíbula associada a bifosfonatos intravenosos em doentes oncológicos.

Acta Médica Portuguesa, 2008
Bisphosphonates are synthetic analogs of inorganic pyrophosphate, which are not only potent inhibitors of osteoclast-mediated bone resorption, but also present an important inhibitory activity of angiogenesis.
Ana Carvalho, Rui Amaral Mendes, Davide Carvalho, João F C Carvalho   +3 more
doaj   +1 more source

Oral Mucosal Ulcer Associated with Improper Usage of Bisphosphonate: A Case Report

Türk Osteoporoz Dergisi, 2023
Bisphosphonates are widely used agents for osteoporosis. Although bisphosphonates are generally well-tolerated drugs, especially oral forms may have gastrointestinal system side effects.
Şeyma Nur Bayındır, Bilinç Doğruöz Karatekin, Afitap İçağasıoğlu   +2 more
doaj   +1 more source

Use of bisphosphonates in bone pathology – benefits and risks [PDF]

Romanian Journal of Rheumatology, 2023
This article aims to establish, on the basis of medical literature and of the authors’ experience, whether bisphosphonates still have a role in treating skeletal diseases, with increased bone resorption. The effects of bisphosphonates on the bone tissue,
Dinu Antonescu, Cristian Ioan Stoica
doaj   +1 more source

Therapeutic potential of bisphosphonates - review of medical indications, mechanism of action, interactions and adverse effects

Journal of Education, Health and Sport
Introduction: Bisphosphonates are pharmacological agents that inhibit bone resorption by targeting osteoclasts, thereby increasing bone density and reducing fracture risk.
Agnieszka Mikosińska, Mateusz Litwin, Jakub Parys, Patrycja Kałuziak, Aleksandra Witek, Martyna Kaźmierczak, Stanisław Jesionek, Marta Jajczak, Maciej Mossakowski   +8 more
doaj   +1 more source

ATYPICAL FRACTURES DUE TO LONG TREATMENT WITH BISPHOSPHONATES (CRITICAL REVIEW)

Travmatologiâ i Ortopediâ Rossii, 2013
This paper reviews the evidence for an association between atypical subtrochanteric fractures and long-term bisphosphonate use. A PubMed search of literature was performed.
G. S. Golubev
doaj   +1 more source

Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication

Saudi Pharmaceutical Journal, 2018
Introduction: In October 2010, the US Food and Drug Administration (FDA) issued a safety communication regarding the risks of atypical fractures of the femur, with bisphosphonates drugs.
Bander Balkhi, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio   +2 more
doaj   +1 more source

The Effects of Low-Dose Bisphosphonate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Patients With Osteoporosis

Annals of Geriatric Medicine and Research, 2016
Background: Osteoporosis is commonly treated with bisphosphonates. These drugs promote osteoclast apoptosis, which suppresses bone resorption. However, the probability of side effects increases with long-term use of bisphosphonates.
Seo Young Lee, Kyoung Min Kim, Sung Hye Kong, Tae Jung Oh, Jae Hoon Moon, Sung Hee Choi, Soo Lim, Hak Chul Jang   +7 more
doaj   +1 more source

Bisphosphonates for osteoarthritis [PDF]

Arthritis Research & Therapy, 2011
Synovitis and subchondral bone turnover are associated with pain in osteoarthritis. Bisphosphonates provide tools for investigating these pathogenic mechanisms and also may have therapeutic potential. Translating preclinical findings into new treatments for human osteoarthritis requires a critical appraisal and refinement of animal models ...
Walsh, David A, Chapman, Victoria
openaire   +2 more sources

Association of oral bisphosphonates with cardioembolic ischemic stroke: a nested case-control study

Frontiers in Pharmacology, 2023
Background: Bisphosphonates have been reported to increase the risk of atrial fibrillation. Therefore, it is conceivable that they may increase the risk of cardioembolic ischemic stroke (IS).
Sara Rodríguez-Martín, Diana Barreira-Hernández, Ramón Mazzucchelli, Miguel Gil, Alberto García-Lledó, Alberto García-Lledó, Laura Izquierdo-Esteban, Ana Pérez-Gómez, Ana Pérez-Gómez, Antonio Rodríguez-Miguel, Francisco J. De Abajo, Francisco J. De Abajo   +11 more
doaj   +1 more source